TY - JOUR
T1 - Introduction
AU - Thomsen, Henrik S.
AU - Marckmann, Peter
PY - 2008/5/1
Y1 - 2008/5/1
N2 - Until recently it was believed that extracellular gadolinium based contrast agents (Gd-CA) were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some Gd-CA may trig the development of nephrogenic systemic fibrosis, a generalized fibrotic disorder, in renal failure patients. This sub-section of European Journal of Radiology covers the current knowledge about NSF from many aspects. The prevention of NSF must be given high priority, but it should not lead to a denial of a well-justified, enhanced MRI examination with a stable agent.
AB - Until recently it was believed that extracellular gadolinium based contrast agents (Gd-CA) were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some Gd-CA may trig the development of nephrogenic systemic fibrosis, a generalized fibrotic disorder, in renal failure patients. This sub-section of European Journal of Radiology covers the current knowledge about NSF from many aspects. The prevention of NSF must be given high priority, but it should not lead to a denial of a well-justified, enhanced MRI examination with a stable agent.
KW - Gadolinium based contrast agents
KW - Late adverse reactions
KW - Nephrogenic systemic fibrosis
UR - http://www.scopus.com/inward/record.url?scp=43049106868&partnerID=8YFLogxK
U2 - 10.1016/j.ejrad.2008.01.022
DO - 10.1016/j.ejrad.2008.01.022
M3 - Editorial
C2 - 18343071
AN - SCOPUS:43049106868
SN - 0720-048X
VL - 66
SP - 153
EP - 159
JO - European Journal of Radiology
JF - European Journal of Radiology
IS - 2
ER -